Revolution Medicines Inc
$ 197.30
1.98%
05 Aug - close price
- Market Cap 41,128,915,000 USD
- Current Price $ 197.30
- High / Low $ 198.29 / 192.56
- Stock P/E N/A
- Book Value 7.49
- EPS -7.12
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.77 %
- 52 Week High 198.29
- 52 Week Low 34.00
About
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Analyst Target Price
$207.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-26 | 2023-11-06 |
| Reported EPS | None | -2.29 | -1.86 | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 |
| Estimated EPS | -1.93 | -1.84 | -1.58 | -1.39 | -1.12 | -1.06 | -0.9645 | -0.88 | -0.76 | -0.72 | -0.88 | -1 |
| Surprise | 0 | -0.45 | -0.28 | -0.22 | -0.19 | -0.07 | -0.1555 | -0.06 | -0.05 | 0.02 | -0.26 | 0.01 |
| Surprise Percentage | None% | -24.4565% | -17.7215% | -15.8273% | -16.9643% | -6.6038% | -16.1223% | -6.8182% | -6.5789% | 2.7778% | -29.5455% | 1% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.93 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVMD
2026-08-05 13:45:35
Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets or maintained "Buy" ratings, citing promising clinical data and regulatory progress. The company's market capitalization has grown to $41.14 billion, indicating strong market belief in its biotechnology advancements.
2026-08-03 20:45:35
Revolution Medicines (RVMD) has seen significant stock price appreciation after its New Drug Application for daraxonrasib was accepted by the FDA for metastatic pancreatic cancer. Despite a 137.32% year-to-date rise, Simply Wall St's narrative suggests RVMD is still undervalued by 8.2% with a fair value of $204.38, driven by its promising RAS(ON) oncology pipeline. However, the company faces risks due to heavy cash usage, no current revenue, and potential trial disappointments or delays.
2026-08-02 22:11:39
Revolution Medicines (RVMD) has seen significant stock price appreciation following the FDA's acceptance of its New Drug Application for daraxonrasib. Despite a 137.32% year-to-date increase, Simply Wall St's analysis suggests RVMD is 8.2% undervalued, with a fair value pegged at $204.38 based on its strong pipeline of oncology treatments. However, the company still faces risks associated with high cash burn and the potential for trial delays.
2026-08-01 11:41:33
The article focuses on the "Price to earnings forward" for Revolution Medicines, Inc. (RVMDW), listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial information related to RVMDW, including market status and data provided by ICE Data Services and FactSet. The page indicates that the market was closed with no trades.
2026-08-01 04:39:51
This page provides financial overview information for Revolution Medicines, Inc. (NASDAQ: RVMD) on TradingView. It indicates that the market is currently closed with no trades and offers access to various financial data points such as statements, statistics, dividends, earnings, and segment performance.
2026-07-31 15:26:24
Revolution Medicines (RVMD) has received FDA priority review for its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for metastatic pancreatic cancer. This decision, backed by positive Phase 3 data, is a significant catalyst for the company, potentially reshaping its investment narrative despite ongoing losses and high spending. Investors will be monitoring Q2 2026 earnings for insights into operational expenses versus pipeline progress, with daraxonrasib's success being key to future financial performance.
